Cover Image
Market Research Report
Product code 
363113

Female Contraception (Women's and Male Health) - Drugs in Development, 2021

Published: | Global Markets Direct | 128 Pages | Delivery time: 1-2 business days

Price

Back to Top
Female Contraception (Women's and Male Health) - Drugs in Development, 2021
Published: December 30, 2021
Global Markets Direct
Content info: 128 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Contraception - Drugs In Development, 2021, provides an overview of the Female Contraception (Women's Health) pipeline landscape.

Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization, and natural methods. Contraception generally works by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization) and preventing a fertilized egg from implanting in the uterus (hormones).

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Contraception - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Female Contraception (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Contraception (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 3, 2, 6, 4, 1, 18 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3 and 2 molecules, respectively.

Female Contraception (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Female Contraception (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Female Contraception (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Female Contraception (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Female Contraception (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Female Contraception (Women's Health)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Female Contraception (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Female Contraception (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Product Code: GMDHC13218IDB

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Female Contraception - Overview
  • Female Contraception - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Female Contraception - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Female Contraception - Companies Involved in Therapeutics Development
  • Female Contraception - Drug Profiles
  • Female Contraception - Dormant Projects
  • Female Contraception - Discontinued Products
  • Female Contraception - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development for Female Contraception, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Female Contraception - Pipeline by Adare Pharma Solutions, 2021
  • Female Contraception - Pipeline by Agile Therapeutics Inc, 2021
  • Female Contraception - Pipeline by Cirqle Biomedical Contraception IVS, 2021
  • Female Contraception - Pipeline by Dare Bioscience Inc, 2021
  • Female Contraception - Pipeline by Evestra Inc, 2021
  • Female Contraception - Pipeline by Evofem Biosciences Inc, 2021
  • Female Contraception - Pipeline by Exeltis Pharmaceuticals Holding SL, 2021
  • Female Contraception - Pipeline by Hervana Ltd, 2021
  • Female Contraception - Pipeline by Insud Pharma, 2021
  • Female Contraception - Pipeline by Luye Pharma Group Ltd, 2021
  • Female Contraception - Pipeline by Lyndra Therapeutics Inc., 2021
  • Female Contraception - Pipeline by MedinCell SA, 2021
  • Female Contraception - Pipeline by Micron Biomedical Inc, 2021
  • Female Contraception - Pipeline by Mithra Pharmaceuticals SA, 2021
  • Female Contraception - Pipeline by Mucommune LLC, 2021
  • Female Contraception - Pipeline by Myovant Sciences Ltd, 2021
  • Female Contraception - Pipeline by Navad Life Sciences Pte Ltd, 2021
  • Female Contraception - Pipeline by Noven Pharmaceuticals Inc, 2021
  • Female Contraception - Pipeline by Ohana BioSciences Inc, 2021
  • Female Contraception - Pipeline by Orion Biotechnology Canada Ltd, 2021
  • Female Contraception - Pipeline by Teva Pharmaceutical Industries Ltd, 2021
  • Female Contraception - Pipeline by Viramal Ltd, 2021
  • Female Contraception - Pipeline by Yaso Therapeutics Inc, 2021
  • Female Contraception - Pipeline by YourChoice Therapeutics Inc, 2021
  • Female Contraception - Pipeline by ZabBio Inc, 2021
  • Female Contraception - Dormant Projects, 2021
  • Female Contraception - Dormant Projects, 2021 (Contd..1)
  • Female Contraception - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Female Contraception, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021